Table 4. Performance of hrHPV testing for the detection of CIN2/3 six months after cryotherapy.

Post- treatment	TP	FP	FN	TN	Sensitivity	Specificity	PPV	NPV
hrHPV	17	39	1	22	0.94 (0.73–1.00)	0.36 (0.24–0.49)	0.30 (.19–0.44)	0.96 (0.78–1.00)
HPV16	7	6	11	55	0.39 (0.17–0.64)	0.90 (0.80–0.96)	0.54 (0.25–0.81)	0.83 (0.72–0.91)
HPV18	4	8	14	53	0.22 (0.06–0.48)	0.87 (0.76–0.94)	0.33 (0.10–0.65)	0.79 (0.67–0.88)
HPV16/18	11	14	7	47	0.61 (0.36–0.83)	0.77 (0.65–0.87)	0.44 (0.24–0.65)	0.87 (0.75–0.95)
Persistent hrHPV1	17	32	1	29	0.94 (0.73–1.00)	0.48 (0.35–0.61)	0.35 (0.22–0.50)	0.97 (0.83–1.00)

Kenya, 79 HIV-positive women.

¹At least 1 same hrHPV type present before and 6 months after cryotherapy.

TP, true positive, FP, false positive, FN, false negative, TN, true negative, PPV, positive predictive value, NPV, negative predictive value, hrHPV, high-risk human papillomavirus.